Published by Iain Gilbert on 11th September 2024
(Sharecast News) - Drugmaker GSK said on Wednesday that primary objective data analysts from a phase II trial of its early-stage therapeutic herpes simplex virus vaccine candidate showed that the drug had failed to meet its primary efficacy objective.
URL: http://www.digitallook.com/dl/news/story/34547397/...